Skip to Content

Fragmin Dosage

Generic name: DALTEPARIN SODIUM 2500[iU] in 0.2mL
Dosage form: injection

Medically reviewed by Drugs.com. Last updated on May 31, 2019.

Recommended Dosage for Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave Myocardial Infarction

In patients with unstable angina or non-Q-wave myocardial infarction, the recommended dose of FRAGMIN Injection is 120 IU/kg of body weight, but not more than 10,000 IU, subcutaneously every 12 hours with concurrent oral aspirin (75 to 165 mg once daily) therapy. Treatment should be continued until the patient is clinically stabilized. The usual duration of administration is 5 to 8 days. Concurrent aspirin therapy is recommended except when contraindicated.

Table 1 lists the volume of FRAGMIN in mL (based on the 3.8 mL multiple-dose vial 25,000 IU/ mL) and quantity of FRAGMIN in IU, to be administered for a range of patient weights.

Table 1 Quantity and Volume of FRAGMIN to be Administered by Patient Weight
Patient weight (lb) <110 110 to 131 132 to 153 154 to 175 176 to 197 ≥198
Patient weight (kg) <50 50 to 59 60 to 69 70 to 79 80 to 89 ≥90
Quantity of FRAGMIN (IU) 5,500 IU 6,500 IU 7,500 IU 9,000 IU 10,000 IU 10,000 IU
Volume of FRAGMIN (mL)
95,000 IU / 3.8 mL
0.22 0.26 0.30 0.36 0.40 0.40

Prophylaxis of Deep Vein Thrombosis

Prophylaxis of VTE Following Hip Replacement Surgery: Table 2 presents the dosing options for patients undergoing hip replacement surgery. The usual duration of administration is 5 to 10 days after surgery; up to 14 days of treatment with FRAGMIN have been well tolerated in clinical trials.

Table 2 Dosing Options for Patients Undergoing Hip Replacement Surgery
Timing of First Dose of FRAGMIN Dose of FRAGMIN to be Given Subcutaneously
10 to 14 Hours Before Surgery Within 2 Hours Before Surgery 4 to 8 Hours After Surgery* Postoperative Period
*
Or later, if hemostasis has not been achieved.
Up to 14 days of treatment was well tolerated in controlled clinical trials, where the usual duration of treatment was 5 to 10 days postoperatively.
Allow a minimum of 6 hours between this dose and the dose to be given on Postoperative Day 1. Adjust the timing of the dose on Postoperative Day 1 accordingly.
§
Allow approximately 24 hours between doses.
Postoperative Start --- --- 2,500 IU 5,000 IU once daily
Preoperative Start - Day of Surgery --- 2,500 IU 2,500 IU 5,000 IU once daily
Preoperative Start - Evening Before Surgery§ 5,000 IU --- 5,000 IU 5,000 IU once daily

Abdominal Surgery: In patients undergoing abdominal surgery with a risk of thromboembolic complications, the recommended dose of FRAGMIN is 2,500 IU administered by subcutaneous injection once daily, starting 1 to 2 hours prior to surgery and repeated once daily postoperatively. The usual duration of administration is 5 to 10 days.

In patients undergoing abdominal surgery associated with a high risk of thromboembolic complications, such as malignant disorder, the recommended dose of FRAGMIN is 5,000 IU subcutaneously the evening before surgery, then once daily postoperatively. The usual duration of administration is 5 to 10 days. Alternatively, in patients with malignancy, 2,500 IU of FRAGMIN can be administered subcutaneously 1 to 2 hours before surgery followed by 2,500 IU subcutaneously 12 hours later, and then 5,000 IU once daily postoperatively. The usual duration of administration is 5 to 10 days.

Medical Patients During Acute Illness: In medical patients with severely restricted mobility during acute illness, the recommended dose of FRAGMIN is 5,000 IU administered by subcutaneous injection once daily. In clinical trials, the usual duration of administration was 12 to 14 days.

Extended Treatment of Symptomatic Venous Thromboembolism (VTE) in Adult Patients with Cancer

In adult patients with cancer and symptomatic VTE, the recommended dosing of FRAGMIN is as follows: for the first 30 days of treatment administer FRAGMIN 200 IU/kg total body weight subcutaneously once daily. The total daily dose should not exceed 18,000 IU. Table 3 lists the dose of FRAGMIN to be administered once daily during the first month for a range of patient weights.

Month 1

Table 3 Dose of FRAGMIN to be Administered Subcutaneously by Patient Weight during the First Month
Body Weight (lbs) Body Weight (kg) FRAGMIN Dose (IU)
(prefilled syringe) once daily
≤124 ≤56 10,000
125 to 150 57 to 68 12,500
151 to 181 69 to 82 15,000
182 to 216 83 to 98 18,000
≥217 ≥99 18,000

Months 2 to 6

Administer FRAGMIN at a dose of approximately 150 IU/kg, subcutaneously once daily during Months 2 through 6. The total daily dose should not exceed 18,000 IU. Table 4 lists the dose of FRAGMIN to be administered once daily for a range of patient weights during months 2–6.

Table 4 Dose of FRAGMIN to be Administered Subcutaneously by Patient Weight during Months 2–6
Body Weight (lbs) Body Weight (kg) FRAGMIN Dose (IU)
(prefilled syringe)
once daily
≤124 ≤56 7,500
125 to 150 57 to 68 10,000
151 to 181 69 to 82 12,500
182 to 216 83 to 98 15,000
≥217 ≥99 18,000

Safety and efficacy beyond six months have not been evaluated in patients with cancer and acute symptomatic VTE [see Warnings and Precaution (5) and Adverse Reactions (6.1)].

Treatment of Symptomatic Venous Thromboembolism (VTE) in Pediatric Patients

The recommended starting dose according to pediatric age is provided in Table 5.

Table 5 Starting Doses for Pediatric Patients with Symptomatic VTE
Age Group Starting Dose
4 Weeks to less than 2 Years 150 IU/kg twice daily
2 Years to less than 8 Years 125 IU/kg twice daily
8 Years to less than 17 Years 100 IU/kg twice daily

After initiation of FRAGMIN, measure anti-Xa level prior to the 4th dose. Samples for anti-Xa level should be drawn 4 hours after administration of FRAGMIN. Adjust doses in increments of 25 IU/kg to achieve target anti-Xa level between 0.5 and 1 IU/mL. Individualize the maintenance dose of FRAGMIN based on the dose that achieves target anti-Xa level collected 4 hours after administration of FRAGMIN. Monitor anti-Xa level periodically in pediatric patients to maintain anti-Xa level between 0.5 and 1 IU/mL [see Clinical Pharmacology (12.3) and Clinical Studies (14.5)].

Whenever possible, administer benzyl alcohol-free formulations (prefilled syringes) in pediatric patients [see Warnings and Precautions (5.3) and Use in Specific Populations (8.4)].

Dose Reductions for Thrombocytopenia in Adult Patients with Cancer and in Pediatric Patients with Symptomatic VTE

Dose reductions recommended in patients receiving FRAGMIN who experience thrombocytopenia are presented below in Table 6.

Table 6
Platelet Count less than or equal to 50,000/mm3 Platelet Count equal to 50,000 to 100,000/mm3
Adults Discontinue FRAGMIN until platelet count recovers to above 50,000/mm3. Reduce the daily dose of FRAGMIN by 2,500 IU until the platelet count recovers to greater or equal to 100,000/mm3.
Children 4 Weeks to less than 17 Years Discontinue FRAGMIN until platelet count recovers to above 50,000/mm3. Reduce the daily dose of FRAGMIN by 50% until the platelet count recovers to greater or equal to 100,000/mm3.

Dose Reductions for Renal Insufficiency in Extended Treatment of Acute Symptomatic VTE in Adult Patients with Cancer

In patients with severely impaired renal function (CrCl <30 mL/min), monitor anti-Xa levels to determine the appropriate FRAGMIN dose. Target anti-Xa range is 0.5–1.5 IU/mL. When monitoring anti-Xa in these patients, perform sampling 4–6 hours after FRAGMIN dosing and only after the patient has received 3–4 doses.

Administration

FRAGMIN is administered by subcutaneous injection. It must not be administered by intramuscular injection.

FRAGMIN Injection should not be mixed with other injections or infusions unless specific compatibility data are available that support such mixing.

Subcutaneous injection technique: Patients should be sitting or lying down and FRAGMIN administered by deep subcutaneous injection. FRAGMIN may be injected in a U-shape area around the navel, the upper outer side of the thigh or the upper outer quadrangle of the buttock. The injection site should be varied daily. When the area around the navel or the thigh is used, using the thumb and forefinger, you must lift up a fold of skin while giving the injection. The entire length of the needle should be inserted at a 45 to 90 degree angle.

Inspect FRAGMIN prefilled syringes and vials visually for particulate matter and discoloration prior to administration

After first penetration of the rubber stopper, store the multiple-dose vials at room temperature for up to 2 weeks. Discard any unused solution after 2 weeks.

Instructions for using the prefilled single-dose syringes preassembled with needle guard devices

Figure

Fixed dose syringes: To ensure delivery of the full dose, do not expel the air bubble from the prefilled syringe before injection. Hold the syringe assembly by the open sides of the device. Remove the needle shield. Insert the needle into the injection area as instructed above. Depress the plunger of the syringe while holding the finger flange until the entire dose has been given. The needle guard will not be activated unless the entire dose has been given. Remove needle from the patient. Let go of the plunger and allow syringe to move up inside the device until the entire needle is guarded. Discard the syringe assembly in approved containers.

Graduated syringes: Hold the syringe assembly by the open sides of the device. Remove the needle shield. With the needle pointing up, prepare the syringe by expelling the air bubble and then continuing to push the plunger to the desired dose or volume, discarding the extra solution in an appropriate manner. Insert the needle into the injection area as instructed above. Depress the plunger of the syringe while holding the finger flange until the entire dose remaining in the syringe has been given. The needle guard will not be activated unless the entire dose has been given. Remove needle from the patient. Let go of the plunger and allow syringe to move up inside the device until the entire needle is guarded. Discard the syringe assembly in approved containers.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide